BEACON: FOR RARE DISEASES LTD
Findacure works to:Empower patient groups to build their patient community, develop as a charity, and drive treatment research and development.Promote collaboration between rare disease stakeholders to facilitate treatment development for all.
Financial health, per its FY2025 accounts
The accounts state that the charity ended the year with a surplus of £29,318 and total funds of £220,802, supported by three long-term funding streams. However, the trustees report that the general unrestricted funds of £67,966 are below the stated policy target of three months' staff costs, which they estimate at a little over £100,000.
What the accounts disclose
“The principal funding source in this period was grant funding from the UKRI to support our work on the REMEDi4ALL project. This grant is paid in arears, with payments to Beacon during this period covering work from December 2023 to November 2024 and totaling £157,773.04.” — page 9
“The general unrestricted funds, which the Trustees have not designated, of £67,966 (2024: £74,613) are below the cost of maintaining our staff team for three months (a little over £100,000)”
Funders the charity credits
- Novartis
- BioMarin
- UCB
- BioMarin Pharmaceuticals
Structured financials (annual return, FY ending 31/01/2025)
Trustees
- ANDREW MILLIGAN
- Dr ANTHONY KENT HALL
- Joanne Patra Pisani
- Kamlesh Kanaiyalal Sheth
- Michael Paul Wilbur
- Scott Robin Hutchings
- Shannon Marie Gunn
- Sophie Costello
Income and spending
| Financial year end | Income | Spending |
|---|---|---|
| 31/01/2025 | £691k | £662k |
| 31/01/2024 | £523k | £479k |
| 31/01/2023 | £324k | £390k |
| 31/01/2022 | £270k | £318k |
| 31/01/2021 | £325k | £196k |
Common questions
Is BEACON: FOR RARE DISEASES LTD financially healthy?
Per its FY2025 accounts: The accounts state that the charity ended the year with a surplus of £29,318 and total funds of £220,802, supported by three long-term funding streams. However, the trustees report that the general unrestricted funds of £67,966 are below the stated policy target of three months' staff costs, which they estimate at a little over £100,000. Its FY2025 accounts were independently examined.
Government & lottery funding
| Funder | Date | Amount | Purpose |
|---|---|---|---|
| The National Lottery Community Fund | 07/05/2024 | £20k | The Cambridge Rare Disease Showcases |
| The National Lottery Community Fund | 17/02/2023 | £10k | The Rare Disease Showcase Series 2023 |
| The National Lottery Community Fund | 20/01/2023 | £404k | The Empowerment Programme: Phase 2 |
| UK government | 04/08/2022 | £151k | BUILDING A SUSTAINABLE EUROPEAN INNOVATION PLATFORM TO ENHANCE THE REPURPOSING OF MEDICINES FOR ALL |
| UK government | 04/08/2022 | £146k | BUILDING A SUSTAINABLE EUROPEAN INNOVATION PLATFORM TO ENHANCE THE REPURPOSING OF MEDICINES FOR ALL |
| UK government | 01/04/2022 | £76k | BUILDING A SUSTAINABLE EUROPEAN INNOVATION PLATFORM TO ENHANCE THE REPURPOSING OF MEDICINES FOR ALL |
| The National Lottery Community Fund | 28/10/2021 | £10k | The Rare Disease Showcase Series 2022 |
| The National Lottery Community Fund | 22/04/2020 | £10k | The Showcase Series |
| The National Lottery Community Fund | 18/04/2019 | £337k | Empowerment Programme |
| The National Lottery Community Fund | 21/10/2015 | £28k | Drug Repurposing for Rare Diseases |
| The National Lottery Community Fund | 28/01/2015 | £10k | Training Videos for Rare Disease Patient Groups |